Long-term safety of selpercatinib for Rearranged during transfection ( <i>RET)</i> -activated advanced solid tumors in LIBRETTO-001: differing patterns of adverse events over time
Long-term treatment with selpercatinib is feasible. AEs are manageable with dose modifications, allowing most patients to continue safely on therapy.
Authors
- Nathan A. Pennell (ORCID: https://orcid.org/0000-0002-1458-0064)
- Luis E. Raez (ORCID: https://orcid.org/0000-0003-2669-5771)
- Ashish C. Massey
- Scott Barker (ORCID: https://orcid.org/0000-0001-9372-6932)
- Katherine Liming
- Patrick Peterson (ORCID: https://orcid.org/0000-0002-2186-6124)
Institutions
- Cleveland Clinic (US)
- Eli Lilly (United States) (US)
- Florida Atlantic University (US)
Publication Details
- Journal
- The Oncologist
- Published
- 2024-10-02
- DOI
- https://doi.org/10.1093/oncolo/oyae282
- Citations
- 7
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 2.00
Funders
- Eli Lilly and Company